Healthy Human, Lung Cancer
Conditions
Brief summary
In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of antiviral therapy and the development of related vaccines. It is also expected to further conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of ACEI/ARB (32). With the development of both molecular imaging agents and related equipment, several ACE2-targeting PET imaging agents have been investigated based on different strategies while some of them were tested in clinical trials. The aim of this study was to intercept key ACE2-binding sites from coronavirus RBD and test their potential as ACE2-targeting PET agents.
Interventions
DRUG68Ga-A3
Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* the ability to provide informed written consent * a medical history without any ACE2-related comorbidities
Exclusion criteria
* liver and renal function dysfunction, * pregnancy or current lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| standardized uptake value (SUV) | through study completion, an average of 1 year | comparing the SUVmean of different organs or lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance | through study completion, an average of 1 year | evaluating the number of lung cancer lesions detected by 68Ga-A3 |
Countries
China
Contacts
Primary ContactZhaohui Zhu, MD
Outcome results
None listed